<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04373057</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00105137</org_study_id>
    <nct_id>NCT04373057</nct_id>
  </id_info>
  <brief_title>Prebiotic Galacto-oligosaccharide and Acute GVHD</brief_title>
  <official_title>A Phase I/II Trial of the Prebiotic Galacto-oligosaccharide to Prevent Acute GVHD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the carbohydrate prebiotic (dietary
      supplement) known as galacto-oligosaccharide (GOS) can modulate the microbiome (the bacteria
      in the gut) and help prevent graft-versus host disease (GVHD) after allogeneic stem cell
      transplant. The study has two two parts. In phase 1, the best dose of GOS will be evaluated.
      In phase 2, using the best dose of GOS, participants will be randomized to receive GOS or a
      placebo (maltodextrin, a common food additive that is not known to affect the microbiome) so
      that the effect of GOS can be determined.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Humans carry on the order of 100 trillion microbial cells (the microbiota),which play a major
      role in normal health as well as disease pathogenesis. In the gut, the microbiota interact
      with the intestinal epithelium and immune system to regulate inflammation and metabolism. The
      impact of the microbiota on GVHD and other clinical outcomes may be mediated by bacterial
      metabolites such as short chain fatty acid (SCFAs). In particular, the SCFA butyrate has been
      shown to be a preferred fuel source of human colonic epithelial cells and essential for
      normal differentiation of regulatory immune cells in the intestine, which in turn may
      decrease GVHD. This is supported by murine studies, in which manipulating the gut microbiota
      to increase microbial SCFA production or by direct administration (oral gavage) of butyrate
      has been shown to improve HCT outcomes, including protection from GVHD

      Manipulating the gut microbiota in HCT to decrease the risk of GVHD could potentially be done
      using several methods, namely prebiotics (dietary carbohydrates or fibers), probiotics (live
      bacteria), and fecal transplantation. In contrast to live bacteria, prebiotics are dietary
      carbohydrates classified as nutritional supplements that can sustain gut bacteria, regulate
      gastrointestinal transit time, and foster cooperative metabolic networks between enteric
      microbes. Because prebiotics encourage the growth of existing bacteria rather than
      introducing new organisms, they may be safer. Moreover, bacterial fermentation of prebiotics
      may yield SCFA.

      The purpose of this study is to determine whether the carbohydrate prebiotic (dietary
      supplement) known as galacto-oligosaccharide (GOS) can modulate the microbiome (the bacteria
      in the gut) and help prevent graft-versus host disease (GVHD) after allogeneic stem cell
      transplant. The study has two two parts. In phase 1, three dose levels 0.75g/day (25% maximum
      dose, D1), 1.5g/day (50% maximum dose D2), and 2.9g/day (maximum dose, D3) will be evaluated
      to find out the provisional maximum tolerated dose (pMTD) of GOS to be used in phase 2. In
      phase 2, using pMTD of GOS, participants will be randomized to receive GOS or a placebo
      (maltodextrin, a common food additive that is not known to affect the microbiome) so that the
      effect of GOS can be determined. Note that if the pMTD is D3, there will be a D1 and D2
      lead-in period similar to the Phase 1 study however if the pMTD is D2, there will only be a
      lead-in with D1 and if pMTD is D1, there will only be one dose with no lead-in. The study
      will generate important data on gut microbiota responses to help tailor or personalize future
      prebiotic therapies to patients and their microbiota.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2020</start_date>
  <completion_date type="Anticipated">September 2025</completion_date>
  <primary_completion_date type="Anticipated">June 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>provisional Maximum Tolerated Dose (pMTD) of GOS</measure>
    <time_frame>30 days</time_frame>
    <description>GOS will be dosed as outlined using a modified 3+3 design: 0.75g x 4 days, followed by 1.5g x 4 days, followed by 2.9g for the duration of the study. If two or more subjects experience new grade 2 or 3 pre-HCT toxicities at a given dose level, that dose will be considered not tolerable and the previous dose pMTD. If two or more subjects experience new grade 2 or higher pre-HCT toxicities at the 0.75g/day dose, study may be paused to revisit the design. If one subject experiences new grade 2 or 3 pre-HCT toxicities at a given dose level, additional 3 subjects will be enrolled at this same dose schedule. If one or more of these additional subjects experience new grade 2 or 3 pre-HCT toxicities at that same or lower dose level, this dose level will be considered not tolerable and the previous dose the pMTD. If no subjects experience new grade 2 or 3 pre-HCT toxicities or only one of six subjects experience new grade 2 or 3 pre-HCT toxicities, 2.9g/day dose will be assumed to be the pMTD</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Grade II-IV acute GVHD at Day 100</measure>
    <time_frame>100 days</time_frame>
    <description>Acute GVHD Scoring will be done following BMT CTN, 2013 criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of acute GI toxicities through Day 30</measure>
    <time_frame>30 days</time_frame>
    <description>Acute GI toxicities include mucositis, nausea, vomiting, diarrhea, constipation, abdominal pain, and bloating through D30 as assessed by CTCAE v5.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidences of Acute GI toxicities as measured by self-reported evaluation through Day 30</measure>
    <time_frame>30 days</time_frame>
    <description>Acute GI toxicities as measured by self-reported (PRO-CTCAE) evaluation of decreased appetite, anxiety, sadness, fatigue, insomnia, general pain, shortness of breath, numbness and tingling, mouth sores, nausea, vomiting, diarrhea, constipation, abdominal pain, and bloating through D 30 (5 point ordinal scale per PRO-CTCAE)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of chronic GVHD at Day 365 and Day 730</measure>
    <time_frame>Day 365 and day 730</time_frame>
    <description>Chronic GVHD Scoring will be done following NIH Consensus Criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health care utilization through Day 100, through Day 365, and through Day 730</measure>
    <time_frame>Day 100, Day 365, and Day 730</time_frame>
    <description>Data will be obtained through chart review at or after Day 100, Day 365, and Day730 (respectively), and will be reported as means/medians depending on the distribution of data (for example, mean/median health care utilization through Day 100)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS) at Day 365 and Day 730</measure>
    <time_frame>Day 365 and Day 730</time_frame>
    <description>Data will be obtained by chart review at or after D365 and D730 Data will be reported as a percentage (ie. 1-year and 2-year overall survival) for each arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse-free survival (RFS) at Day 365 and Day 730</measure>
    <time_frame>Day 365 and Day 730</time_frame>
    <description>Data will be obtained by chart review at or after Day 365 and Day 730 Data will be reported as a percentage (ie. 1-year and 2-year overall survival) for each arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total parenteral nutrition (TPN) use through Day 30 and Day 100</measure>
    <time_frame>Day 30 and Day 100</time_frame>
    <description>Data will be obtained as part of the GVHD Prophylaxis/medication assessments. Data will be reported as a percentage for each arm (at each of the time points)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">128</enrollment>
  <condition>Acute GVHD</condition>
  <arm_group>
    <arm_group_label>Galacto-oligosaccharide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase I: Subjects will receive GOS, at dose levels 0.75g, 1.5g, and 2.9 g/day administered once daily. GOS will be dosed per the following schedule using a modified 3+3 design: 0.75g x 4 days, followed by 1.5g x 4 days, followed by 2.9g for the duration of the study starting from about 30 days before transplant to about 4 weeks after transplant.
Phase II: Subjects will receive GOS, at dose levels 0.25*MTD, 0.5*MTD, and MTD with MTD determined by the phase 1 of the study, once daily from about 30 days before transplant to about 4 weeks after transplant.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Maltodextrin</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Phase II: Subjects will receive maltodextrin at comparable dose level as GOS (in Phase II) once daily from about 30 days before transplant to about 4 weeks after transplant.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Galacto-oligosaccharide</intervention_name>
    <description>GOS will be administered at determined dose levels per protocol once daily from about 30 days before transplant to about 4 weeks after transplant.</description>
    <arm_group_label>Galacto-oligosaccharide</arm_group_label>
    <other_name>BimunoÂ®, B-GOS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Maltodextrin</intervention_name>
    <description>Maltodextrin will be administered at comparable dose level as GOS (in Phase II) once daily from about 30 days before transplant to about 4 weeks after transplant.</description>
    <arm_group_label>Maltodextrin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Plan to undergo allogeneic HCT for any cancer or non-cancer illness

          -  Age 18-80 years

          -  Karnofsky Performance Status &gt;70

        Exclusion Criteria:

          -  Pregnant/lactating

          -  Malabsorption syndrome, short bowel or chologenic diarrhea

          -  At time of enrollment, Grade 2 or higher GI symptoms per NCI-CTCAE

          -  Active treatment with other prebiotics, probiotics, or herbal supplementation (ok if
             stops before enrollment)

          -  Active treatment with antibiotics (with the exception of prophylactic antibiotics)

          -  Concurrent enrollment on the Duke HCT Home Transplant study or another clinical trial
             targeting GVHD; patients who are enrolled in observational or non-pharmacologic
             intervention trials (for example, the Duke HCT Research-POP Pre and Peri-HCT
             Optimization Program aka &quot;R-POP&quot;) or pharmacologic or cellular therapy trials with
             other targets (for example, NK DLI) are NOT excluded
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anthony Sung, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University Health System</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Meagan Lew</last_name>
    <phone>919 681 5027</phone>
    <email>meagan.lew@duke.edu</email>
  </overall_contact>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>April 29, 2020</study_first_submitted>
  <study_first_submitted_qc>May 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 4, 2020</study_first_posted>
  <last_update_submitted>May 1, 2020</last_update_submitted>
  <last_update_submitted_qc>May 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

